← All trials
NCT05727683
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Jul 31, 2025
- First posted
- Feb 14, 2023
- Last posted
- Feb 14, 2023
- Enrollment
- 33
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Ming Ju Biotechnology Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.